+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Seborrhea - Pipeline Review, H2 2020

  • ID: 5146876
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 50 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Arcutis Inc
  • Cutanea Life Sciences Inc
  • DermBiont Inc
  • Vyome Therapeutics Inc
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H2 2020, provides an overview of the Seborrhea (Dermatology) pipeline landscape.

Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews the key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Discovery and Unknown stages are 1, 2, 1 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Arcutis Inc
  • Cutanea Life Sciences Inc
  • DermBiont Inc
  • Vyome Therapeutics Inc
Introduction

Report Coverage
  • Seborrhea - Overview
  • Seborrhea - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Seborrhea - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Seborrhea - Companies Involved in Therapeutics Development
  • Aclaris Therapeutics Inc
  • Arcutis Inc
  • Cutanea Life Sciences Inc
  • DermBiont Inc
  • Vyome Therapeutics Inc
Seborrhea - Drug Profiles
  • ARQ-154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DBI-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Seborrhea - Dormant Projects
  • Seborrhea - Discontinued Products
  • Seborrhea - Product Development Milestones
Featured News & Press Releases
  • Jun 22, 2020: Arcutis enrolls last patient in phase 2 proof of concept clinical trial evaluating ARQ-154 (Topical Roflumilast Foam) as a potential treatment for Seborrheic Dermatitis
  • Dec 05, 2019: Arcutis announces ARQ-154 program for seborrheic dermatitis and enrollment of first patient in phase 2 proof of concept clinical trial
  • Feb 28, 2019: Aclaris Therapeutics Receives European Approvals of ESKATA (hydrogen peroxide) cutaneous solution, 685 mg
  • Dec 18, 2018: Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
  • Oct 01, 2018: Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA (hydrogen peroxide) Topical Solution 40%, (w/w)
  • Jun 12, 2018: Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris ESKATA is safe and effective in treating persons with raised seborrheic keratoses
  • May 30, 2018: Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA
  • May 16, 2018: Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting
  • May 07, 2018: Aclaris Therapeutics Announces Availability of ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w)
  • Feb 08, 2018: Aclaris Therapeutics to Present Data on ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) at the 2018 American Academy of Dermatology Annual Meeting
  • Dec 15, 2017: Aclaris Therapeutics Receives FDA Approval for ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
  • Sep 19, 2017: Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis
  • Aug 03, 2017: Aclaris Therapeutics Submits Marketing Authorization Application in Europe for A-101 40% Topical Solution as a Novel Treatment for Seborrheic Keratosis
  • Jun 13, 2017: Aclaris Therapeutics Announces Issuance of New US Patent For A-101 Topical Solutions
  • May 09, 2017: FDA Accepts Aclaris Therapeutics' New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Seborrhea, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Seborrhea - Pipeline by Aclaris Therapeutics Inc, H2 2020
  • Seborrhea - Pipeline by Arcutis Inc, H2 2020
  • Seborrhea - Pipeline by Cutanea Life Sciences Inc, H2 2020
  • Seborrhea - Pipeline by DermBiont Inc, H2 2020
  • Seborrhea - Pipeline by Vyome Therapeutics Inc, H2 2020
  • Seborrhea - Dormant Projects, H2 2020
  • Seborrhea - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Seborrhea, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Aclaris Therapeutics Inc
  • Arcutis Inc
  • Cutanea Life Sciences Inc
  • DermBiont Inc
  • Vyome Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll